1
|
Showalter CA, Rajasekera P, Biehn S, Pérez-Soto B, Lindert S, Bennett C, McElroy J, Manring H, Haque SJ, Chakravarti A. In Silico Discovery and Investigation of Novel Small Molecules Targeting PSMA7 for the Treatment of GBM. Int J Radiat Oncol Biol Phys 2023; 117:S43. [PMID: 37784498 DOI: 10.1016/j.ijrobp.2023.06.317] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/04/2023]
Abstract
PURPOSE/OBJECTIVE(S) The five-year survival rate for glioblastoma (GBM; WHO grade 4) remains only 5%, even with the current standard treatment of maximal safe surgical tumor resection followed by radiation treatment (RT) and concomitant and adjuvant temozolomide (TMZ). Therefore, alternative treatment therapies, such as blood-brain barrier (BBB)-permeable small molecule drugs, are needed to significantly improve patient outcomes by addressing other critical pathways in GBM progression and overcome GBM resistance to the standard treatment. Previously, we identified and validated proteasome subunit alpha type-7 (PSMA7), a subunit of the 20S proteasome, as a druggable, therapeutically vulnerable target in GBM by in vitro and in vivo methods. In this study, we performed in silico molecular docking screenings using a small molecule library to identify BBB-permeable small molecules predicted to bind to PSMA7 and investigated their potential as novel therapeutics for the treatment of GBM. MATERIALS/METHODS In silico molecular docking screenings were performed using the National Cancer Institute Diversity Set VI small molecule library and the crystal structure of PSMA7 obtained from the native human 20S proteasome (RCSB PDB: 5LE5). Molecules were scored based on their predicted likelihood to bind to PSMA7. Top ranked molecules were screened using the SwissADME webtool, to select molecules predicted to be BBB-permeable and not a substrate for the permeability glycoprotein (P-gp), for testing with in vitro studies. Then, in vitro cell viability assays were used to determine IC50 values for molecules in human GBM PDX and normal human cell lines. The potential for molecules to sensitize GBM cells towards TMZ and/or RT was evaluated in vitro. In vitro proteasome activity assays were used to investigate whether molecules altered the three major protease activities performed by the proteasome. RESULTS Computational virtual screenings using two docking algorithms (i.e., AutoDock Vina and Glide XP) identified and ranked the top small molecules most likely to bind to PSMA7. In silico screening using the SwissADME webtool predicted 99 of these molecules to be BBB-permeable and not a substrate for the P-gp. Subsequent in vitro cell viability studies determined eight of these molecules have lower IC50 values in human GBM PDX cells compared to normal human cells. Furthermore, we examined the potential of these eight molecules to sensitize GBM cells to TMZ and/or RT in vitro. Moreover, we found that three of these molecules inhibited all three major protease activities performed by the proteasome in GBM cells. CONCLUSION Our study identified BBB-permeable small molecules predicted to target PSMA7 that demonstrated greater toxicity to GBM cells than normal cells and inhibited proteasome activities, suggesting a potential mechanism of action. Taken together, these small molecules are potential candidates for preclinical studies and may serve as novel targeted therapies for the treatment of GBM.
Collapse
Affiliation(s)
- C A Showalter
- Department of Radiation Oncology, Arthur G. James Hospital/Ohio State Comprehensive Cancer Center, Columbus, OH
| | - P Rajasekera
- Department of Radiation Oncology, Arthur G. James Hospital/Ohio State Comprehensive Cancer Center, Columbus, OH
| | - S Biehn
- Department of Chemistry & Biochemistry, The Ohio State University, Columbus, OH
| | - B Pérez-Soto
- Department of Chemistry & Biochemistry, The Ohio State University, Columbus, OH
| | - S Lindert
- Department of Chemistry & Biochemistry, The Ohio State University, Columbus, OH
| | - C Bennett
- Drug Development Institute, Comprehensive Cancer Center, The Ohio State University, Columbus, OH
| | - J McElroy
- The Ohio State University, Center for Biostatistics, Department of Biomedical Informatics, Columbus, OH
| | - H Manring
- The Ohio State University Comprehensive Cancer Center, Columbus, OH
| | - S J Haque
- Department of Radiation Oncology, Arthur G. James Hospital/Ohio State Comprehensive Cancer Center, Columbus, OH
| | - A Chakravarti
- Department of Radiation Oncology, Arthur G. James Hospital/Ohio State Comprehensive Cancer Center, Columbus, OH
| |
Collapse
|
2
|
Kumar A, Rajasekera P, Becker V, Biehn S, Pérez-Soto B, Beyer S, McElroy J, Becker A, Johnson B, Cui T, Sebastian E, Grosu A, Lindert S, Bell EH, Manring H, Haque J, Chakravarti A. Hypoxia-Inducible Transgelin-2 Confers Treatment Resistance through Activation of PI3K/Akt/GSK3β Pathway in Glioblastoma. Int J Radiat Oncol Biol Phys 2023; 117:e121. [PMID: 37784671 DOI: 10.1016/j.ijrobp.2023.06.910] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/04/2023]
Abstract
PURPOSE/OBJECTIVE(S) Glioblastoma (GBM) patients with wild-type IDH experience worse survival response to the standard treatment of surgery followed by radiation therapy (RT) and temozolomide (TMZ) chemotherapy compared to their mutant IDH counterparts. This treatment has remained relatively ineffective partly due to the highly invasive phenotype of GBM leading to therapeutic resistance and tumor recurrence. Hypoxia is one of the key characteristic features of GBM which results in cancer metastasis and confers treatment resistance. Therefore, it is paramount to identify targets to help overcome hypoxia-induced treatment resistance in glioblastoma. Our lab has identified transgelin-2 (TAGLN2) to be significantly upregulated in IDH-wt GBM through multiple molecular profiling studies. This study aims to understand the mechanisms by which TAGLN2 confers treatment resistance for developing additional treatments for GBM. Additionally, active drug development efforts are also underway to target TAGLN2 for circumventing these therapeutic resistance mechanisms for effective GBM therapy. MATERIALS/METHODS RNAi-mediated TAGLN2 knockdown (KD) approach was employed to assess the functions of TAGLN2 in GBM patient-derived xenograft (PDX) cell lines. Series of in vitro functional assays were performed to assess the role of TAGLN2 in these cell lines. Cell proliferation, invasion ± RT and/or TMZ were assessed by MTS and Trans-well invasion assays. Subsequently, WB analysis of oncogenic signaling pathways was performed following Transgelin-2 KD. Co-IP assays and Biacore/SPR analyses were performed to study the binding affinity and kinetics for the interaction of PTEN with TAGLN2. Further, cells were intracranially implanted in nude mice to assess the role of TAGLN2 on tumor growth in vivo. RESULTS Conditional KD of TAGLN2 reduces cell proliferation, survival and invasive potential of GBM PDX cell lines. TAGLN2 KD also improved the sensitivity of these cells to both TMZ and radiation in vitro, as assessed by proliferation, survival, clonal expansion, and invasion. Histopathological studies of human GBM tumors and mouse xenograft tumors showed elevated expression of TAGLN2 in the peri-necrotic region of the tumors indicating that TAGLN2 protein level was upregulated by hypoxia. We also show that TAGLN2 is induced in hypoxic microenvironments with GBM PDX cell lines and its overexpression may enhance cellular resistance towards conventional therapy. Subsequently, we also show that hypoxia-induced TAGLN2 activates the PI3K/Akt oncogenic pathway through binding and inhibition of PTEN. Finally, in vivo data using an orthotopic xenograft mouse model shows reduction of tumor growth with knockdown of TAGLN2. CONCLUSION Our in vitro and in vivo xenograft studies suggest that TAGLN2 confers treatment resistance to GBM contributing to tumor recurrence. Altogether, TAGLN2 may serve as a potential therapeutically vulnerable target in GBM specifically through its role in cell survival and invasion.
Collapse
Affiliation(s)
- A Kumar
- Department of Radiation Oncology, Arthur G. James Hospital Ohio State Comprehensive Cancer Center, Columbus, OH
| | - P Rajasekera
- Department of Radiation Oncology, Arthur G. James Hospital/The Ohio State University Wexner Medical Center/Comprehensive Cancer Center, Columbus, OH
| | - V Becker
- 1Department of Radiation Oncology, Arthur G. James Hospital/Ohio State Comprehensive Cancer Center, Columbus, OH
| | - S Biehn
- Department of Chemistry & Biochemistry, The Ohio State University, Columbus, OH
| | - B Pérez-Soto
- Department of Chemistry & Biochemistry, The Ohio State University, Columbus, OH
| | - S Beyer
- Department of Radiation Oncology, The Ohio State University Wexner Medical Center, Columbus, OH
| | - J McElroy
- The Ohio State University, Center for Biostatistics, Department of Biomedical Informatics, Columbus, OH
| | - A Becker
- The Ohio State University Comprehensive Cancer Center, Columbus, OH
| | - B Johnson
- The Ohio State University, Columbus, OH
| | - T Cui
- The Department of Radiation Oncology, City of Hope National Medical Center, Duarte, CA
| | - E Sebastian
- Department of Radiation Oncology, Arthur G. James Hospital/The Ohio State University Wexner Medical Center/Comprehensive Cancer Center, Columbus, OH
| | - A Grosu
- German Cancer Consortium (DKTK), Partner Site Freiburg, Heidelberg, Germany
| | - S Lindert
- Department of Chemistry & Biochemistry, The Ohio State University, Columbus, OH
| | - E H Bell
- Administrative Director, Neuroscience Research Institute, Columbus, OH
| | - H Manring
- The Ohio State University Comprehensive Cancer Center, Columbus, OH
| | - J Haque
- The Ohio State University Comprehensive Cancer Center, Columbus, OH
| | - A Chakravarti
- The Ohio State University Comprehensive Cancer Center, Columbus, OH
| |
Collapse
|